Biosimilar Monoclonal Antibodies

monoclonal antibody (mAb) is originally produced by a single B-cell. Biosimilars are a lot complicated than small-molecule medicine and generics. In the past few years, monoclonal antibody drugs have dominated the world's largest biopharmaceutical drug sales, and in the coming years, monoclonal antibody drugs will continue to be the main force. Considering the huge profit margins and potential market, the monoclonal antibody-based therapeutics is the hot territory many pharmaceutical companies chases. This session will summarize the market in terms of therapeutic applications, type, and structure of mAbs, dominant companies, manufacturing locations, and emerging markets. These requirements would lead to greater development in the process and tighter quality controls during the production of biosimilar mAbs.

  • FDA-approved mAb drugs
  • Monoclonal antibody therapy
  • Anti-Cancer Antibodies
  • Cancer Immune therapy
  • Antibody Humanization Technologies
  • Biotherapeutics : Early Analytical Development

Related Conference of Biosimilar Monoclonal Antibodies

November 26-27, 2019

International Conference On Genomics and Molecular Biology

Lisbon, Portugal | Holiday Inn Lisbon-Continental Rua Laura Alves 9, 1069-169 Lisboa, Portugal
November 26-27, 2019

International Conference on Cell and Gene Therapy

Lisbon, Portugal | Holiday Inn Lisbon-Continental Rua Laura Alves 9, 1069-169 Lisboa, Portugal
February 24-25, 2020

24th Global Congress on Biotechnology

London, UK
June 28-30 2020

Stroke Summit 2020

July 15-16, 2020

12th World Congress and Expo on Stem Cell Research

Prague, Czech Republic
15-11-2020

molecularbiology-cs-2020

UAE,Dubai
December 07- 08, 2020

2nd World Congress on Cell and Structural Biology

Sydney, Australia

Biosimilar Monoclonal Antibodies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in